Skip to content

Hair Labs · Kensington, London · Batch 001.

The future is bright.

You are holding Anti Grey 1.0 — the first protocol from a London hair-biology research practice. This page is a short orientation to what you have started, and what we are building beyond it.

What to expect.

A short note for someone who has just started the protocol.

Daily.

Two capsules, with food. The protocol works on cadence, not events.

Quality first.

Texture, strength, and shedding tend to move before pigment. Weeks, not months.

Pigment is slower.

New growth carries the protocol's signal. Months, not weeks.

The practice.
The field, today.

Hair ageing is a slow, multi-system process. Six biological drivers; finite legible windows; one published protocol so far. The work is to keep the lens trained on the field as the literature deepens.

2005.

Nishimura et al. — Mechanisms of hair greying: incomplete melanocyte stem-cell maintenance in the niche.

2020.

Zhang et al. — Hyperactivation of sympathetic nerves drives depletion of melanocyte stem cells.

2023.

Sun et al. — Dedifferentiation maintains melanocyte stem cells in a dynamic niche.

2024.

Iida et al. — Luteolin protects melanocyte stem cells from greying in vivo.

The next formulations.

These are research directions, not product promises.

01.

Anti Grey, refined as the published literature deepens.

02.

A second formulation under early research.

03.

A third formulation, further out, paced by the field.

Journal.

Continued publication of consolidated chapters between formulations.

The Hair Labs Club.

For founder clients of Batch 001.

A quiet membership for the founder cohort. As the practice grows, your protocol carries with it.

Consultations.
Consultations. Direct access to the Clinical Advisory Board route and partner trichologists for protocol-specific questions.
Partner clinics.
Partner clinics. Member rates at clinic partners for trichology, scalp imaging, and supporting diagnostics.
Batch priority.
Batch priority. First access to subsequent batches and to future formulations as they are released.
Journal preview.
Journal preview. Quiet early access to forthcoming Journal chapters before public publication.

No fee. Founder access carries forward.

Authored in Kensington.

This page is a small thank-you for joining Batch 001. The protocol you are starting is the first publication of a research practice that intends to keep publishing — a Journal, a Research surface, a Clinical Advisory Board, and a slow line of formulations as the literature supports them.

The future is bright because the field is finally legible.

Arthur Corvin Powells. · Co-founder · Kensington.

Continue.